We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Enzon Pharmaceuticals Inc.s financial performance into perspective.
Quickly sort and find the exact file you need here. Send the files directly into your Shareholder Briefcase or read and right click "save target as" individual files.
| Title | Date | Type | Size | ||||
|---|---|---|---|---|---|---|---|
| 2010 Revised Proxy Statement |
|
142.7 KB | |||||
| 2010 Proxy Statement |
|
314.4 KB | |||||
| 2009 Annual Report |
|
2.5 MB | |||||
| 2008 Annual Report |
|
1.6 MB | |||||
| 2009 Proxy Statement | 2009 |
|
353.9 KB | ||||
| 2009 Proxy Card | Apr 13, 2009 |
|
29.0 KB | ||||
| Enzon_2009_PhRMA_Code_CEO_CCO_certification.pdf |
|
30.8 KB | |||||
| 2007 Annual Report | 2007 |
|
1.3 MB | ||||
| Governance and Nominating Committee |
|
N/A | |||||
| Finance and Audit Committee |
|
N/A | |||||
|
|||||||
| (ENZN) NASDAQ | |
| Last Trade | 10.580 |
| Change(%) |
0.17
|
| Volume | 208,700 |
| Sep 2, 2010 4:00 PM ET | |
Sign up to receive Enzon Pharmaceuticals Inc. financial information by email.
News
Details on upcoming events are not yet available.
click here to be notified of all upcoming events.


Really Simple Syndication is a format designed for sharing web content such as headlines. An RSS feed highlights fresh material for you, so you don't have to repeatedly check a site yourself for updates.
Company continues to progress as an innovative oncology
development company
--Company is transformed to be exclusively focused on its pipeline--
